OBJECTIVE: Antiretroviral (ARV) therapies fail when behavioral or biologic factors lead to inadequate medication exposure. The currently available methods to assess ARV exposure are limited. Levels of ARVs in hair reflect plasma concentrations over weeks to months, and may provide a novel method for predicting therapeutic responses. DESIGN/ METHODS: The Women's Interagency HIV Study, a prospective cohort of HIV-infected women, provided the basis for developing and assessing methods to measure commonly prescribed protease inhibitors (lopinavir/ritonavir and atazanavir) in small hair samples. We examined the association between hair protease inhibitor levels and initial virologic responses to therapy in multivariate logistic regression models. RESULTS: ARV concentrations in hair were strongly and independently associated with treatment response for 224 women starting a new protease inhibitor-based regimen. For participants initiating lopinavir/ritonavir, the odds ratio (OR) for virologic suppression was 39.8 [95% confidence interval (CI) = 2.8-564] for those with lopinavir hair levels in the top tertile (>1.9 ng/mg) compared to the bottom (</=0.41 ng/mg) when controlling for self-reported adherence, age, race, starting viral load and CD4 cell count, and prior experience with protease inhibitors. For women starting atazanavir, the adjusted OR for virologic success was 7.7 (95% CI = 2.0-29.7) for those with hair concentrations in the top tertile (>3.4 ng/mg) compared to the lowest (</=1.2 ng/mg). CONCLUSION: Protease inhibitor levels in small hair samples were the strongest independent predictor of virologic success in a diverse group of HIV-infected adults. This non-invasive method for determining ARV exposure may have particular relevance for the epidemic in resource-poor settings due to the ease of collecting and storing hair.
OBJECTIVE: Antiretroviral (ARV) therapies fail when behavioral or biologic factors lead to inadequate medication exposure. The currently available methods to assess ARV exposure are limited. Levels of ARVs in hair reflect plasma concentrations over weeks to months, and may provide a novel method for predicting therapeutic responses. DESIGN/ METHODS: The Women's Interagency HIV Study, a prospective cohort of HIV-infectedwomen, provided the basis for developing and assessing methods to measure commonly prescribed protease inhibitors (lopinavir/ritonavir and atazanavir) in small hair samples. We examined the association between hair protease inhibitor levels and initial virologic responses to therapy in multivariate logistic regression models. RESULTS: ARV concentrations in hair were strongly and independently associated with treatment response for 224 women starting a new protease inhibitor-based regimen. For participants initiating lopinavir/ritonavir, the odds ratio (OR) for virologic suppression was 39.8 [95% confidence interval (CI) = 2.8-564] for those with lopinavir hair levels in the top tertile (>1.9 ng/mg) compared to the bottom (</=0.41 ng/mg) when controlling for self-reported adherence, age, race, starting viral load and CD4 cell count, and prior experience with protease inhibitors. For women starting atazanavir, the adjusted OR for virologic success was 7.7 (95% CI = 2.0-29.7) for those with hair concentrations in the top tertile (>3.4 ng/mg) compared to the lowest (</=1.2 ng/mg). CONCLUSION:Protease inhibitor levels in small hair samples were the strongest independent predictor of virologic success in a diverse group of HIV-infected adults. This non-invasive method for determining ARV exposure may have particular relevance for the epidemic in resource-poor settings due to the ease of collecting and storing hair.
Authors: Melanie C Bacon; Viktor von Wyl; Christine Alden; Gerald Sharp; Esther Robison; Nancy Hessol; Stephen Gange; Yvonne Barranday; Susan Holman; Kathleen Weber; Mary A Young Journal: Clin Diagn Lab Immunol Date: 2005-09
Authors: Nancy A Hessol; Susan Holman; Howard Minkoff; Mardge H Cohen; Elizabeth T Golub; Seble Kassaye; Roksana Karim; Oluwakemi Sosanya; Christopher Shaheen; Zaher Merhi Journal: AIDS Care Date: 2015-08-14
Authors: Nhi Phung; Karen Kuncze; Hideaki Okochi; Alexander Louie; Leslie Z Benet; Igho Ofokotun; David W Haas; Judith S Currier; Tariro D Chawana; Anandi N Sheth; Peter Bacchetti; Monica Gandhi; Howard Horng Journal: Rapid Commun Mass Spectrom Date: 2018-03-15 Impact factor: 2.419
Authors: Marya Gwadz; Charles M Cleland; Elizabeth Applegate; Mindy Belkin; Monica Gandhi; Nadim Salomon; Angela Banfield; Noelle Leonard; Marion Riedel; Hannah Wolfe; Isaiah Pickens; Kelly Bolger; DeShannon Bowens; David Perlman; Donna Mildvan Journal: AIDS Behav Date: 2015-10
Authors: Roy Gerona; Anita Wen; David Aguilar; Jamie Shum; Andrew Reckers; Peter Bacchetti; Monica Gandhi; John Metcalfe Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2019-07-23 Impact factor: 3.205
Authors: Gert U van Zyl; Lisa M Frenkel; Michael H Chung; Wolfgang Preiser; John W Mellors; Jean B Nachega Journal: AIDS Date: 2014-11-28 Impact factor: 4.177
Authors: Peter K Olds; Julius P Kiwanuka; Denis Nansera; Yong Huang; Peter Bacchetti; Chengshi Jin; Monica Gandhi; Jessica E Haberer Journal: AIDS Care Date: 2014-12-06
Authors: Carola R Röhrich; Britt I Drögemöller; Ogechi Ikediobi; Lize van der Merwe; Nelis Grobbelaar; Galen E B Wright; Nathaniel McGregor; Louise Warnich Journal: AIDS Res Hum Retroviruses Date: 2016-01-29 Impact factor: 2.205